NQO1 and familial pancreatic carcinoma: Notably, we found that KP372-1 is at least ~ 10- to 20-fold more potent than another NQO1 substrate, β-lap (ARQ761, under phase 1 clinical trials against pancreatic cancers, NCT02514031).